MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Microscopic polyangiitis; Wegener's granulomatosis
- Focus Therapeutic Use
- Acronyms MAINRITSAN 2
- 18 Nov 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2016.
- 16 Nov 2016 Results analysing ANCA-associated vasculitides relapses presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
- 14 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Oct 2017.